IO-108 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IO-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IO-108 overview
IO-108 is under development for the treatment of solid tumors, merkel cell carcinoma, bile duct cancer (cholangiocarcinoma), metastatic and/or unresectable hepatocellular carcinoma, colorectal cancer. The drug candidate acts by targeting leukocyte immunoglobulin-like receptor B2. It is administered through intravenous route.
Immune Onc Therapeutics overview
Immune Onc Therapeutics (Immune-Onc) is a cancer immunotherapy company. It discovers and develops new immunomodulatory approaches to treat immunology and inflammation, blood cancers, and solid tumors. The company aims to translate unique scientific insights into the immune suppressive pathways and tumor microenvironment to develop first-in-class biotherapeutics. Immune-Onc develops a novel class of antibodies that modulate or deplete specific subsets of myeloid cells involved in disease pathogenesis. It identifies and utilizes antibodies targeting an immune inhibitory receptor for the treatment of acute myeloid leukemia (AML) and other cancers. Its pipeline product includes IO-202, for acute myeloid leukemia and other hematologic and solid tumors. Immune-Onc is headquartered in Palo Alto, California, the US.
For a complete picture of IO-108’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
